AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast
21 juil. 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular...
AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests
27 avr. 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye...
AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch
15 févr. 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
AXIM is driven to positively transform the state of Dry Eye Disease (DED) testing and diagnosis The company will deploy industry leader IUL’s state-of-the-art iPeak readers Company Adds Veteran Lab...
AXIM Biotechnologies’ Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90% Sensitivity and 100% Specificity
09 nov. 2021 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19...
AXIM Biotechnologies Appoints Clinical Research and DED Expert Dr. Michael E. Stern to its Medical Advisory Board
02 nov. 2021 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological,...
AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19
12 oct. 2021 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological,...
AXIM® Biotechnologies to Acquire Technology Including Two FDA-Cleared 510(k)’s for Diagnostic Testing of Dry Eye Disease
03 août 2021 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a leader in the development of diagnostic testing for COVID-19 and...
AXIM® Biotechnologies Nutraceutical Division Announces Cannabinoid-Based Wellness Gum Product Line at Benzinga Cannabis Capital Conference
22 oct. 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development, announced...
Axim® Biotechnologies Begins Manufacturing Cannabinoid-Based Gum With Dronabinol for Use in Upcoming Pre-Clinical Studies
10 sept. 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK , Sept. 10, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development, announced...
New U.S. Patent Allowance Granted To Axim® Biotechnologies For Anti-Microbial Compositions Comprising Cannabinoids
08 août 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today...